Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 8Uterine Cervical Neoplasms 5Melanoma 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Neoplasms 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Endometrial Neoplasms 3Prostatic Neoplasms 2Kidney Neoplasms 2Colonic Neoplasms 2Carcinoma, Merkel Cell 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Thyroid Neoplasms 1Skin Neoplasms 1Sarcoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

pembrolizumab 13Nivolumab 6Gemcitabine 5Paclitaxel 4Cisplatin 4Magnetic Resonance Spectroscopy 3Ipilimumab 3Fluorouracil 3Fluorodeoxyglucose F18 3Carboplatin 3spartalizumab 2fludarabine 2budigalimab 2Oxaliplatin 2Leucovorin 2Irinotecan 2FAPI-46 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Bevacizumab 2venetoclax 1ulixertinib 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × cemiplimab × Gynecologic × Clear all
NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡